La Jolla Pharmaceutical Co's revenue for the
three
months ended in Jun. 2022 was $10.54 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2022 was $46.49 Mil.
La Jolla Pharmaceutical Co's Revenue per Share for the
three
months ended in Jun. 2022 was $0.33.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $1.49.
Warning Sign:
La Jolla Pharmaceutical Co revenue per share is in decline over the past 12 months.
During the past 13 years, La Jolla Pharmaceutical Co's highest 3-Year average Revenue per Share Growth Rate was 186.90% per year. The lowest was 0.00% per year. And the median was 78.70% per year.
La Jolla Pharmaceutical Co Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of La Jolla Pharmaceutical Co's Revenue
For the Biotechnology subindustry, La Jolla Pharmaceutical Co's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
La Jolla Pharmaceutical Co's Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, La Jolla Pharmaceutical Co's Revenue distribution charts can be found below:
* The bar in red indicates where La Jolla Pharmaceutical Co's Revenue falls into.
La Jolla Pharmaceutical Co Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $46.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
La Jolla Pharmaceutical Co (NAS:LJPC) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
La Jolla Pharmaceutical Co Revenue Related Terms
Thank you for viewing the detailed overview of La Jolla Pharmaceutical Co's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
La Jolla Pharmaceutical Co (La Jolla Pharmaceutical Co) Business Description
La Jolla Pharmaceutical Co is a biopharmaceutical company. The company's main activity is the discovery, development, and commercialization of innovative therapies that improve patients' life-threatening conditions. The company's portfolio consists of an angiotensin II formulation, which regulates blood pressure; a formulation of hepcidin, an endogenous peptide hormone that regulates iron metabolism; and an antibiotic approved by the U.S. Food and Drug Administration.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LJPC has been successfully added to your 